ArticleBMJ public health2024
Negotiation of new international health law on intellectual property, technology transfer, open science and pathogen access and benefit sharing: a textual and contextual analysis.
Article in BMJ public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global vaccine development.Nature medicine · 2026Review
- Open Science, Health Data and Epistemic Harms: A Multidisciplinary Reflection.Data science journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This original research article reframes new international law and policy developments at the intersections of open science, technology transfer, intellectual property and access and sharing the benefits of biomedical innovation in the context of global pandemics. Methods: Through textual and contextual analysis, using the lens of national experiences and negotiating positions of one high-income country, Canada, it traces the evolution of legal normative developments from a proposed waiver of aspects of the World Trade Organisation Agreement on Trade-Related Aspects of Intellectual Property Rights through a forum shift to negotiate a new agreement for pandemic preparedness and response (the Pandemic Agreement) at the WHO. Results: The analysis shows a significant evolution of treaty provisions on R&D, sustainable and diversified production of pandemic-related products, transfer of technology and know-how and access and benefit sharing. Juxtaposed against a Canadian parliamentary report, stakeholder consultations and Canada's stated commitment to equity, the negotiating texts reflect major compromises on the key issues. High-income countries sought open access to pathogen gene sequence data crucial for pandemic prevention, preparedness and response while resisting measures other than voluntarily licensing on mutually agreed terms of private intellectual property rights derived from the use of such data or other publicly funded research. Low- and middle-income countries, meanwhile, were offered diluted language on technology transfer in exchange for a new pathogen access and benefit-sharing scheme. Conclusions: The practical effects of these compromises remain to be seen, but they risk exacerbating rather than ameliorating global health inequities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.